Amino Compounds Inhibit Factor D Complement Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement cascade, such as age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, lack effective small molecule inhibitors for Factor D, leading to inadequate control of excessive immune responses and inflammatory disorders.
Innovation Solution
Development of specific amino compounds, including those listed in Table 1, Table 2, and Table 3, which are administered to modulate the complement pathway by inhibiting Factor D, thereby reducing detrimental complement activity and treating associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement-mediated disorders are used, then existing therapeutic options are available, but effective control of excessive immune responses is inadequate
Solution Approach 1:
The patent employs small molecule inhibitors as disposable, non-biological agents that can be administered systemically without requiring complex delivery mechanisms. These small molecules act transiently to inhibit Factor D, providing reliable control of complement activation without the need for long-term biological agents
Solution Approach 2:
The invention changes the chemical parameters of Factor D inhibitors by developing novel small molecule structures with specific chemical groups and molecular weights optimized for binding to Factor D. This parameter optimization enables effective inhibition of Factor D activity, improving reliability of complement pathway control
2Speed
If the alternative pathway of the complement cascade is activated, then rapid response to pathogenic organisms is achieved, but detrimental inflammatory responses occur
Solution Approach 1:
The patent introduces small molecule inhibitors as intermediary agents that selectively bind to Factor D, blocking its interaction with Factor B in the alternative pathway. This intermediary action allows the system to maintain rapid response capability while preventing harmful inflammatory amplification by intercepting the complement cascade at the Factor D step
Solution Approach 2:
The invention applies partial inhibition of the alternative pathway by selectively targeting Factor D without completely blocking all complement functions. This partial action allows beneficial rapid response to pathogens while preventing excessive inflammatory responses, achieving balance between speed and harm reduction
3Reliability
If Factor H function is insufficient, then genetic risk for macular degeneration increases, but complement activation control is compromised
Solution Approach 1:
The patent enables the complement system to self-regulate by providing small molecule inhibitors that restore balance when natural regulatory mechanisms (Factor H) are insufficient. The inhibitors serve the system's own regulatory needs by preventing uncontrolled activation, allowing the body to maintain complement activation control even with genetic deficiencies
Solution Approach 2:
The invention provides beforehand protection by administering small molecule inhibitors that preemptively block Factor D activity, cushioning against the harmful effects of uncontrolled complement activation that would otherwise occur in individuals with Factor H deficiencies. This prior cushioning prevents cellular damage before it can occur
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.